SAGE
Sage Therapeutics Inc
Halal Rating :
Last Price
$7.07
Last updated:
Market Cap
-
7D Change
-5.73%
1 Year Change
-73.09%
Company Overview
Industries
Exchange
Next Earnings Date
Sage Therapeutics is a biopharmaceutical company focused on developing and commercializing novel medicines to treat central nervous system (CNS) disorders. The company's primary focus is on developing treatments for depression, neurology, and neuropsychiatry. Their lead products include ZURZUVAE™ (zuranolone) for postpartum depression and ZULRESSO™ (brexanolone) CIV injection for postpartum depression.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| Sept. 30, 2024 | $11.87m | $113.07m | - | - | 0.00% | 0.00% |
| June 30, 2024 | $8.65m | $119.95m | - | - | 0.00% | 0.00% |
| March 31, 2024 | $7.9m | $125.58m | - | - | 0.00% | 0.00% |
Company Impact
Help us evaluate Sage Therapeutics Inc's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.